Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontamalimab Long-term Extension in Crohn's Disease
NCT01298492Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2011
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of ontamalimab in Crohn's disease, sponsored by Takeda. Primary endpoint: Number of Participants With On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs) at Week 72. Started Jul 2011; status: completed.
02
Drugs
ontamalimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01298492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298492.